我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
1
33.3%
招募中
2
66.7%
暂无批准数据
- Australian researchers at The University of Queensland have dosed the first five participants in a groundbreaking clinical trial of ASITI-201, an immunotherapy designed to rebalance immune response in Type 1 diabetes. - The novel treatment combines pancreatic protein fragments with vitamin D to prevent immune attacks on insulin-producing cells, potentially preserving pancreatic function and reducing insulin dependence in recently diagnosed patients. - If successful, the therapy could fundamentally change treatment approaches by addressing the root cause of Type 1 diabetes, with future applications potentially including prevention in high-risk individuals and adaptation for other autoimmune conditions.
